Published in PLoS Negl Trop Dis on April 27, 2010
A systematic review of mathematical models of mosquito-borne pathogen transmission: 1970-2010. J R Soc Interface (2013) 2.14
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog (2013) 1.47
An essential role of antibodies in the control of Chikungunya virus infection. J Immunol (2013) 1.31
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med (2012) 1.29
Arboviral encephalitides: transmission, emergence, and pathogenesis. J Neuroimmune Pharmacol (2010) 1.24
Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine (2011) 1.17
A mathematical model of chikungunya dynamics and control: the major epidemic on Réunion Island. PLoS One (2013) 1.17
Updating the geographical distribution and frequency of Aedes albopictus in Brazil with remarks regarding its range in the Americas. Mem Inst Oswaldo Cruz (2014) 1.14
Chikungunya virus nsP3 blocks stress granule assembly by recruitment of G3BP into cytoplasmic foci. J Virol (2012) 1.12
Inflammatory cytokine expression is associated with chikungunya virus resolution and symptom severity. PLoS Negl Trop Dis (2011) 1.12
Future infectious disease threats to Europe. Am J Public Health (2011) 1.09
Clinical forms of chikungunya in Gabon, 2010. PLoS Negl Trop Dis (2012) 1.07
Chikungunya outbreak in Guangdong Province, China, 2010. Emerg Infect Dis (2012) 1.07
Travel-associated illness trends and clusters, 2000-2010. Emerg Infect Dis (2013) 1.05
Structural and functional insights into alphavirus polyprotein processing and pathogenesis. Proc Natl Acad Sci U S A (2012) 1.01
Comparing dengue and chikungunya emergence and endemic transmission in A. aegypti and A. albopictus. J Theor Biol (2014) 1.01
Chikungunya virus with E1-A226V mutation causing two outbreaks in 2010, Guangdong, China. Virol J (2013) 0.98
Antiviral activity of silymarin against chikungunya virus. Sci Rep (2015) 0.93
Infection by chikungunya virus modulates the expression of several proteins in Aedes aegypti salivary glands. Parasit Vectors (2012) 0.88
Developing a vulnerability mapping methodology: applying the water-associated disease index to dengue in Malaysia. PLoS One (2013) 0.87
Functional characterization of the alphavirus TF protein. J Virol (2013) 0.86
Chikungunya in the Caribbean: An Epidemic in the Making. Infect Dis Ther (2014) 0.86
A model for a chikungunya outbreak in a rural Cambodian setting: implications for disease control in uninfected areas. PLoS Negl Trop Dis (2014) 0.86
DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis (2014) 0.85
Insecticide resistance to organophosphates in Culex pipiens complex from Lebanon. Parasit Vectors (2012) 0.84
Chikungunya fever outbreak, Bhutan, 2012. Emerg Infect Dis (2013) 0.84
Induction of cytopathogenicity in human glioblastoma cells by chikungunya virus. PLoS One (2013) 0.84
First report of naturally infected Aedes aegypti with chikungunya virus genotype ECSA in the Americas. PLoS Negl Trop Dis (2017) 0.84
In vivo imaging of chikungunya virus in mice and Aedes mosquitoes using a Renilla luciferase clone. Vector Borne Zoonotic Dis (2011) 0.82
Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library. PLoS Negl Trop Dis (2013) 0.82
Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice. J Virol (2013) 0.81
Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Proc Natl Acad Sci U S A (2015) 0.81
Ckikungunya virus infection and relationship to rainfall, the relationship study from southern Thailand. J Arthropod Borne Dis (2013) 0.79
Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line. PLoS One (2014) 0.79
Probing the early temporal and spatial interaction of the Sindbis virus capsid and E2 proteins with reverse genetics. J Virol (2012) 0.78
Mosquito Rasputin interacts with chikungunya virus nsP3 and determines the infection rate in Aedes albopictus. Parasit Vectors (2015) 0.78
First case of imported chikungunya infection in Croatia, 2016. Int Med Case Rep J (2017) 0.78
DNA-launched live-attenuated vaccines for biodefense applications. Expert Rev Vaccines (2016) 0.78
Regulation of Viral Replication, Apoptosis and Pro-Inflammatory Responses by 17-AAG during Chikungunya Virus Infection in Macrophages. Viruses (2017) 0.77
Evaluating the effectiveness of localized control strategies to curtail chikungunya. Sci Rep (2016) 0.77
Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine. Viral Immunol (2013) 0.77
Chikungunya risk for Brazil. Rev Saude Publica (2015) 0.77
Chikungunya fever in Canada: fever and polyarthritis in a returned traveller. CMAJ (2014) 0.77
Genomes to hits in silico - a country path today, a highway tomorrow: a case study of chikungunya. Curr Pharm Des (2013) 0.75
20-hydroxyecdysone mediates non-canonical regulation of mosquito vitellogenins through alternative splicing. Insect Mol Biol (2014) 0.75
Severe Chikungunya infection in Northern Mozambique: a case report. BMC Res Notes (2017) 0.75
Molecular Differentiation of the African Yellow Fever Vector Aedes bromeliae (Diptera: Culicidae) from Its Sympatric Non-vector Sister Species, Aedes lilii. PLoS Negl Trop Dis (2015) 0.75
Characterization of chikungunya virus-like particles. PLoS One (2014) 0.75
Characterization of β-d-N(4)-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. Antimicrob Agents Chemother (2017) 0.75
Next generation sequencing of DNA-launched Chikungunya vaccine virus. Virology (2016) 0.75
HLA class II allele polymorphism in an outbreak of chikungunya fever in Middle Andaman, India. Immunology (2013) 0.75
Neglected atypical pyridoxine dependent seizures. Iran J Pediatr (2010) 0.75
A large-scale stochastic spatiotemporal model for Aedes albopictus-borne chikungunya epidemiology. PLoS One (2017) 0.75
Towards a Hybrid Agent-based Model for Mosquito Borne Disease. Summer Comput Simul Conf (2014) (2014) 0.75
First Report of the East-Central South African Genotype of Chikungunya Virus in Rio de Janeiro, Brazil. PLoS Curr (2017) 0.75
Community context and sub-neighborhood scale detail to explain dengue, chikungunya and Zika patterns in Cali, Colombia. PLoS One (2017) 0.75
Development of in-house serological methods for diagnosis and surveillance of chikungunya. Rev Panam Salud Publica (2017) 0.75
Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet (2007) 10.81
A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog (2007) 10.38
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus. PLoS One (2007) 4.95
An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg (1955) 4.94
An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. II. General description and epidemiology. Trans R Soc Trop Med Hyg (1955) 4.83
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis (2007) 3.87
Vectors of Chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med Hyg (1999) 3.56
A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog (2008) 3.40
Characterization of reemerging chikungunya virus. PLoS Pathog (2007) 3.22
Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic. J Gen Virol (2007) 2.86
Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis (2006) 2.78
Entomology. A mosquito goes global. Science (2008) 2.68
Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis (2009) 2.54
Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Réunion. PLoS Med (2008) 2.49
A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. J Gen Virol (2008) 2.05
IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS One (2009) 2.04
Susceptibility of selected strains of Aedes aegypti and Aedes albopictus (Diptera: Culicidae) to chikungunya virus. J Med Entomol (1992) 1.91
Clinical burden of chikungunya virus infection. Lancet Infect Dis (2008) 1.87
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg (2008) 1.83
Chimeric alphavirus vaccine candidates for chikungunya. Vaccine (2008) 1.78
Molecular diagnosis and analysis of Chikungunya virus. J Clin Virol (2007) 1.78
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine (1986) 1.74
Arthritides caused by mosquito-borne viruses. Annu Rev Med (1982) 1.73
Chikungunya: a paradigm of emergence and globalization of vector-borne diseases. Med Clin North Am (2008) 1.69
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
Neurologic manifestations of pediatric chikungunya infection. J Child Neurol (2008) 1.66
Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res (2008) 1.64
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther (2008) 1.58
Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J Infect Dis (2008) 1.48
Mother-to-child transmission of Chikungunya virus infection. Pediatr Infect Dis J (2007) 1.33
Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine (2009) 1.32
Evaluation of the first commercial chikungunya virus indirect immunofluorescence test. J Virol Methods (2008) 1.26
Susceptibility of Florida mosquitoes to infection with chikungunya virus. Am J Trop Med Hyg (2008) 1.24
Development of monoclonal antibody based antigen capture ELISA to detect chikungunya virus antigen in mosquitoes. Indian J Med Res (2002) 1.23
Chikungunya virus infection. Med J Malaysia (2006) 1.21
Dengue viruses can infect human primary lung epithelia as well as lung carcinoma cells, and can also induce the secretion of IL-6 and RANTES. Virus Res (2007) 1.20
DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol (2006) 1.18
Automatic outbreak detection algorithm versus electronic reporting system. Emerg Infect Dis (2008) 1.17
Dengue haemorrhagic fever-induced acute kidney injury without hypotension, haemolysis or rhabdomyolysis. Nephrol Dial Transplant (2007) 1.15
Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis (1998) 1.09
Evolutionary rates and timescale comparison of Chikungunya viruses inferred from the whole genome/E1 gene with special reference to the 2005-07 outbreak in the Indian subcontinent. Infect Genet Evol (2008) 1.05
Arboviruses associated with human disease in Australia. Microbes Infect (2000) 1.04
The large form of human 2',5'-Oligoadenylate Synthetase (OAS3) exerts antiviral effect against Chikungunya virus. Virology (2008) 1.03
Thrombocytopenia in dengue fever. Curr Hematol Rep (2005) 1.02
Total synthesis of +-superstolide A. J Am Chem Soc (2008) 1.02
Persisting mixed cryoglobulinemia in Chikungunya infection. PLoS Negl Trop Dis (2009) 1.00
Optic neuritis associated with chikungunya virus infection in South India. Arch Ophthalmol (2007) 0.99
Tenosynovitis and vascular disorders associated with Chikungunya virus-related rheumatism. Clin Infect Dis (2007) 0.97
Focus on Chikungunya pathophysiology in human and animal models. Microbes Infect (2009) 0.95
Chikungunya Fever resurgence and global warming. Am J Trop Med Hyg (2007) 0.93
Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology (2009) 0.93
Expression and evaluation of Chikungunya virus E1 and E2 envelope proteins for serodiagnosis of Chikungunya virus infection. Yonsei Med J (2008) 0.90
Chikungunya virus-induced myopericarditis: toward an increase of dilated cardiomyopathy in countries with epidemics? Am J Trop Med Hyg (2008) 0.88
An imported case of Chikungunya fever from Madagascar: use of the sentinel traveller for detecting emerging arboviral infections in tropical and European countries. Travel Med Infect Dis (2008) 0.88
Chikungunya: a review. Trop Doct (2008) 0.87
The biology of chikungunya: a brief review of what we still do not know. Pathol Biol (Paris) (2008) 0.80
Atypical dengue fever mimicking typhoid fever in a college student traveler. Am J Med (2009) 0.77
[Cases of Chikungunya fever in Italy in travellers returning from the Indian Ocean and risk of introduction of the disease to Italy]. Infez Med (2006) 0.77
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol (2002) 3.96
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One (2008) 1.80
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J Immunol (2003) 1.59
SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol (2005) 1.57
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine (2005) 1.56
An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine (2012) 1.52
Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther (2009) 1.44
Molecular genetic relationship of the 3' untranslated region among Thai dengue-3 virus, Bangkok isolates, during 1973-2000. DNA Cell Biol (2009) 1.42
Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther (2006) 1.41
Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 1.40
DNA vaccines: developing new strategies to enhance immune responses. Immunol Res (2008) 1.36
HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem (2002) 1.31
Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis (2002) 1.30
DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A (2009) 1.30
Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS (2002) 1.27
Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25
Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 1.25
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 1.23
Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol (2008) 1.23
Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol (2008) 1.22
From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol (2006) 1.21
Functional characterization of MHC class II-restricted CD8+CD4- and CD8-CD4- T cell responses to infection in CD4-/- mice. J Immunol (2004) 1.19
Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J Allergy Clin Immunol (2005) 1.19
DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol (2006) 1.18
Role of proinflammatory cytokines and chemokines in chronic arthropathy in CHIKV infection. Viral Immunol (2011) 1.16
Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) 1.16
Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol (2008) 1.15
Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine (2010) 1.13
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther (2010) 1.12
Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol (2011) 1.12
The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol (2006) 1.12
HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol (2004) 1.11
Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev (2004) 1.10
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine (2005) 1.09
DNA vaccines: crossing a line in the sand. Introduction to special issue. Vaccine (2008) 1.06
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther (2013) 1.05
Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology (2005) 1.05
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine (2011) 1.04
Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04
Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol (2006) 1.03
Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology (2003) 1.03
Cytokines as adjuvants for improving anti-HIV responses. AIDS (2008) 1.03
HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One (2013) 1.03
HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation. Blood (2005) 1.02
Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med (2007) 1.02
Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem Biophys Res Commun (2003) 1.02
Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. AIDS (2004) 1.02
H2S as an indicator of water supply vulnerability and health risk in low-resource settings: a prospective cohort study. Am J Trop Med Hyg (2013) 1.01
Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine (2009) 1.00
DNA drugs come of age. Sci Am (2010) 0.99
Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine (2005) 0.99
Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Mol Ther (2011) 0.98